Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Madrigal Pharmaceuticals

DB:YDO1
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YDO1
DB
$928M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Madrigal Pharmaceuticals has significant price volatility in the past 3 months.
YDO1 Share Price and Events
7 Day Returns
-15.6%
DB:YDO1
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-55.5%
DB:YDO1
-13.2%
DE Biotechs
-20.9%
DE Market
YDO1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Madrigal Pharmaceuticals (YDO1) -15.6% -29.9% -31.3% -55.5% 283.8% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • YDO1 underperformed the Biotechs industry which returned -13.2% over the past year.
  • YDO1 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
YDO1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Madrigal Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Madrigal Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Madrigal Pharmaceuticals.

DB:YDO1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:YDO1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (0.07%))
1.126
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.126 * 5.44%)
5.74%

Discounted Cash Flow Calculation for DB:YDO1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Madrigal Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:YDO1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.74%)
2020 -107.54 Analyst x3 -101.70
2021 -157.76 Analyst x4 -141.11
2022 -166.87 Analyst x4 -141.15
2023 -26.84 Analyst x4 -21.47
2024 221.17 Analyst x4 167.34
2025 359.01 Est @ 62.32% 256.89
2026 515.22 Est @ 43.51% 348.65
2027 671.53 Est @ 30.34% 429.77
2028 813.36 Est @ 21.12% 492.30
2029 932.65 Est @ 14.67% 533.87
Present value of next 10 years cash flows $1,823.00
DB:YDO1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $932.65 × (1 + -0.39%) ÷ (5.74% – -0.39%)
$15,161.88
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $15,161.88 ÷ (1 + 5.74%)10
$8,679.01
DB:YDO1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,823.00 + $8,679.01
$10,502.01
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,502.01 / 15.43
$680.66
DB:YDO1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:YDO1 represents 0.88142x of NasdaqCM:MDGL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88142x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 680.66 x 0.88142
€599.95
Value per share (EUR) From above. €599.95
Current discount Discount to share price of €53.00
= -1 x (€53.00 - €599.95) / €599.95
91.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Madrigal Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €53 vs Future cash flow value of €599.95
Current Discount Checks
For Madrigal Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Madrigal Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Madrigal Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Madrigal Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Madrigal Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YDO1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-5.45
NasdaqCM:MDGL Share Price ** NasdaqCM (2020-04-03) in USD $60.13
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Madrigal Pharmaceuticals.

DB:YDO1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MDGL Share Price ÷ EPS (both in USD)

= 60.13 ÷ -5.45

-11.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Madrigal Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Madrigal Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:YDO1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
53%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Madrigal Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Madrigal Pharmaceuticals's assets?
Raw Data
DB:YDO1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $27.00
NasdaqCM:MDGL Share Price * NasdaqCM (2020-04-03) in USD $60.13
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:YDO1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MDGL Share Price ÷ Book Value per Share (both in USD)

= 60.13 ÷ 27.00

2.23x

* Primary Listing of Madrigal Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Madrigal Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Madrigal Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Madrigal Pharmaceuticals expected to grow at an attractive rate?
  • Madrigal Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Madrigal Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Madrigal Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:YDO1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:YDO1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 53%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YDO1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YDO1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,050 328 487 7
2023-12-31 444 39 107 7
2022-12-31 75 -156 -132 9
2021-12-31 0 -166 -168 12
2020-12-31 0 -101 -132 12
2020-04-06
DB:YDO1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -42 -84
2019-09-30 -36 -68
2019-06-30 -30 -55
2019-03-31 -23 -42
2018-12-31 -26 -33
2018-09-30 -25 -30
2018-06-30 -25 -30
2018-03-31 -27 -32
2017-12-31 -22 -31
2017-09-30 -22 -30
2017-06-30 -26 -36
2017-03-31 -21 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Madrigal Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Madrigal Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YDO1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YDO1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 19.44 81.98 -5.78 9.00
2023-12-31 3.96 28.89 -9.58 9.00
2022-12-31 -7.30 1.40 -11.73 9.00
2021-12-31 -11.05 -7.28 -17.96 11.00
2020-12-31 -8.39 -7.99 -9.62 8.00
2020-04-06
DB:YDO1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -5.45
2019-09-30 -4.40
2019-06-30 -3.57
2019-03-31 -2.75
2018-12-31 -2.22
2018-09-30 -2.11
2018-06-30 -2.22
2018-03-31 -2.46
2017-12-31 -2.54
2017-09-30 -2.54
2017-06-30 -3.25
2017-03-31 -3.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Madrigal Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Madrigal Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Madrigal Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Madrigal Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Madrigal Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Madrigal Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Madrigal Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Madrigal Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Madrigal Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YDO1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -83.95 22.65 72.32
2019-09-30 -67.68 23.19 56.29
2019-06-30 -54.77 23.56 43.05
2019-03-31 -41.53 19.17 32.56
2018-12-31 -32.81 15.29 25.39
2018-09-30 -29.78 12.11 23.03
2018-06-30 -29.63 8.94 23.50
2018-03-31 -31.52 7.85 25.21
2017-12-31 -31.15 7.67 24.39
2017-09-30 -30.46 6.91 23.40
2017-06-30 -36.14 9.14 24.53
2017-03-31 -30.67 8.06 19.80
2016-12-31 -26.39 6.59 15.93
2016-09-30 -20.52 5.10 11.18
2016-06-30 -8.27 1.12 4.06
2016-03-31 -7.18 0.83 2.60
2015-12-31 -6.84 0.81 2.43
2014-12-31 -4.49 0.55 0.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Madrigal Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Madrigal Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Madrigal Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Madrigal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Madrigal Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Madrigal Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.9649420903391E+18x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago.

DB:YDO1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 416.57 0.00 439.05
2019-09-30 440.35 0.00 453.61
2019-06-30 456.99 0.00 466.40
2019-03-31 468.51 0.00 477.83
2018-12-31 476.98 0.00 483.72
2018-09-30 482.91 0.00 488.54
2018-06-30 486.09 0.00 490.31
2018-03-31 177.18 0.00 182.83
2017-12-31 182.26 0.00 191.53
2017-09-30 54.31 0.00 62.14
2017-06-30 61.63 0.00 67.17
2017-03-31 34.45 0.00 40.13
2016-12-31 36.41 0.00 40.50
2016-09-30 37.59 0.00 39.56
2016-06-30 -42.28 45.97 4.10
2016-03-31 -50.63 50.82 0.62
2015-12-31 -48.91 49.10 0.31
2014-12-31 -42.07 42.19 0.15
  • Madrigal Pharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Madrigal Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 36.4% each year.
X
Financial health checks
We assess Madrigal Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Madrigal Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Madrigal Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Madrigal Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Madrigal Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Madrigal Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YDO1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YDO1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Madrigal Pharmaceuticals has not reported any payouts.
  • Unable to verify if Madrigal Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Madrigal Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Madrigal Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Madrigal Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Madrigal Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Madrigal Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Madrigal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Friedman
COMPENSATION $5,628,666
AGE 76
TENURE AS CEO 3.8 years
CEO Bio

Dr. Paul A. Friedman, M.D., has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. since July 22, 2016 and served as its President since July 22, 2016. Dr. Friedman served as a Member of Synta Pharmaceuticals Corp.’s Board of Directors from March 2014 until April 2016. Dr. Friedman served as the Chief Executive Officer and a Director of Incyte Corporation from November 2001 until his retirement in January 2014. From 1994 to 1998, he served as President of Research & Development for the DuPont-Merck Pharmaceutical Company; and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman currently sits on the Board of Directors of Cerulean Pharma Inc., a publicly traded pharmaceutical company, Verastem, Inc., a publicly traded pharmaceutical company, Incyte Corporation, a publicly traded pharmaceutical company, and Gliknik, Inc. He has previously served on the Board of Directors of Auxilium Pharmaceuticals Inc., a publicly traded pharmaceutical company, and Durata Therapeutics, Inc., a publicly traded pharmaceutical company. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Madrigal Pharmaceuticals management team in years:

3.8
Average Tenure
66
Average Age
  • The tenure for the Madrigal Pharmaceuticals management team is about average.
Management Team

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$6M
AGE
76
TENURE
3.8 yrs

Becky Taub

TITLE
Founder
COMPENSATION
$4M
AGE
67

Marc Schneebaum

TITLE
Senior VP & CFO
COMPENSATION
$3M
AGE
65
TENURE
3.8 yrs

Brian Lynch

TITLE
Senior VP & General Counsel
AGE
58
TENURE
1.2 yrs

Tom Hare

TITLE
Senior Vice President of Clinical Management
Board of Directors Tenure

Average tenure and age of the Madrigal Pharmaceuticals board of directors in years:

3.8
Average Tenure
71
Average Age
  • The tenure for the Madrigal Pharmaceuticals board of directors is about average.
Board of Directors

Becky Taub

TITLE
Founder
COMPENSATION
$4M
AGE
67
TENURE
8.6 yrs

Ken Bate

TITLE
Independent Director
COMPENSATION
$2M
AGE
69
TENURE
3.8 yrs

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$6M
AGE
76
TENURE
3.8 yrs

Keith Gollust

TITLE
Independent Director
COMPENSATION
$2M
AGE
73
TENURE
3.8 yrs

Rich Levy

TITLE
Independent Director
COMPENSATION
$2M
AGE
61
TENURE
3.7 yrs

Fred Craves

TITLE
Lead Director
COMPENSATION
$2M
AGE
73
TENURE
3.8 yrs

Dave Milligan

TITLE
Independent Director
COMPENSATION
$2M
AGE
78
TENURE
3.8 yrs

Jim Daly

TITLE
Independent Director
AGE
57
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Dec 19 Sell Bay City Capital LLC Company 13. Dec 19 13. Dec 19 -1,200,000 €94.82 €-113,781,036
X
Management checks
We assess Madrigal Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Details
Name: Madrigal Pharmaceuticals, Inc.
YDO1
Exchange: DB
Founded: 2011
$859,936,137
15,429,154
Website: http://www.madrigalpharma.com
Address: Madrigal Pharmaceuticals, Inc.
Four Tower Bridge,
Suite 400,
West Conshohocken,
Pennsylvania, 19428,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MDGL New Common Stock Nasdaq Capital Market US USD 25. Jul 2016
DB YDO1 New Common Stock Deutsche Boerse AG DE EUR 25. Jul 2016
LSE 0JXI New Common Stock London Stock Exchange GB USD 25. Jul 2016
Number of employees
Current staff
Staff numbers
29
Madrigal Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:29
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/05
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.